{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:28:59Z","timestamp":1768264139958,"version":"3.49.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,25]]},"DOI":"10.7759\/cureus.84768","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T12:11:03Z","timestamp":1748175063000},"source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Potential of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Liver Disease: Focus on Cirrhosis"],"prefix":"10.7759","author":[{"given":"Hatem","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameh","family":"Gomaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyad","family":"Abdulrazzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imad","family":"Alabdul Razzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kellen K","family":"Kovalovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i41.5910","article-title":"Epidemiology of liver cirrhosis and associated complications: current knowledge and future directions","volume":"28","author":"Liu YB","year":"2022","unstructured":"Liu YB, Chen MK. Epidemiology of liver cirrhosis and associated complications: current knowledge and future directions. World J Gastroenterol. 2022, 28:5910-30. 10.3748\/wjg.v28.i41.5910","journal-title":"World J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101233","article-title":"Mechanisms and implications of recompensation in cirrhosis","volume":"6","author":"Piano S","year":"2024","unstructured":"Piano S, Reiberger T, Bosch J. Mechanisms and implications of recompensation in cirrhosis. JHEP Rep. 2024, 6:101233. 10.1016\/j.jhepr.2024.101233","journal-title":"JHEP Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.5997","article-title":"Diagnosis and management of cirrhosis and its complications: a review","volume":"329","author":"Tapper EB","year":"2023","unstructured":"Tapper EB, Parikh ND. Diagnosis and management of cirrhosis and its complications: a review. JAMA. 2023, 329:1589-602. 10.1001\/jama.2023.5997","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2012.746389","article-title":"Combining transient elastography with FIB4 enhances sensitivity in detecting advanced fibrosis of the liver","volume":"48","author":"Lannerstedt H","year":"2013","unstructured":"Lannerstedt H, Konopski Z, Sandvik L, Haaland T, L\u00f8berg EM, Haukeland JW. Combining transient elastography with FIB4 enhances sensitivity in detecting advanced fibrosis of the liver. Scand J Gastroenterol. 2013, 48:93-100. 10.3109\/00365521.2012.746389","journal-title":"Scand J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon V","year":"2015","unstructured":"Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015, 66:255-70. 10.1146\/annurev-med-051013-110046","journal-title":"Annu Rev Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076039","article-title":"Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond glycemic control","volume":"24","author":"Youssef ME","year":"2023","unstructured":"Youssef ME, Yahya G, Popoviciu MS, Cavalu S, Abd-Eldayem MA, Saber S. Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond glycemic control. Int J Mol Sci. 2023, 24:6039. 10.3390\/ijms24076039","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa JI","year":"2021","unstructured":"Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med (Lausanne). 2021, 8:777861. 10.3389\/fmed.2021.777861","journal-title":"Front Med (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters AL","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015, 38:1687-93. 10.2337\/dc15-0843","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqab157","article-title":"SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD","volume":"162","author":"Ala M","year":"2021","unstructured":"Ala M. SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD. Endocrinology. 2021, 162:bqab157. 10.1210\/endocr\/bqab157","journal-title":"Endocrinology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00795-022-00334-9","article-title":"Hepatic expression of sodium-glucose cotransporter 2 (SGLT2) in patients with chronic liver disease","volume":"55","author":"Nakano D","year":"2022","unstructured":"Nakano D, Akiba J, Tsutsumi T, Kawaguchi M, Yoshida T, Koga H, Kawaguchi T. Hepatic expression of sodium-glucose cotransporter 2 (SGLT2) in patients with chronic liver disease. Med Mol Morphol. 2022, 55:304-15. 10.1007\/s00795-022-00334-9","journal-title":"Med Mol Morphol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12980","article-title":"Effects of canagliflozin on body composition and hepatic fat content in type\u00a02 diabetes patients with non-alcoholic fatty liver disease","volume":"10","author":"Inoue M","year":"2019","unstructured":"Inoue M, Hayashi A, Taguchi T, et al.. Effects of canagliflozin on body composition and hepatic fat content in type\u00a02 diabetes patients with non-alcoholic fatty liver disease. J Diabetes Investig. 2019, 10:1004-11. 10.1111\/jdi.12980","journal-title":"J Diabetes Investig"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2015.10.003","article-title":"Effect of canagliflozin on liver function tests in patients with type 2 diabetes","volume":"42","author":"Leiter LA","year":"2016","unstructured":"Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab. 2016, 42:25-32. 10.1016\/j.diabet.2015.10.003","journal-title":"Diabetes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri H","year":"2020","unstructured":"Taheri H, Malek M, Ismail-Beigi F, Zamani F, Sohrabi M, Reza Babaei M, Khamseh ME. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther. 2020, 37:4697-708. 10.1007\/s12325-020-01498-5","journal-title":"Adv Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3413","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: a meta-analysis of randomized clinical trials","volume":"37","author":"Coelho FD","year":"2021","unstructured":"Coelho FD, Borges-Canha M, von Hafe M, et al.. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: a meta-analysis of randomized clinical trials. Diabetes Metab Res Rev. 2021, 37:e3413. 10.1002\/dmrr.3413","journal-title":"Diabetes Metab Res Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-024-02158-z","article-title":"Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan","volume":"59","author":"Kawaguchi T","year":"2024","unstructured":"Kawaguchi T, Fujishima Y, Wakasugi D, Io F, Sato Y, Uchida S, Kitajima Y. Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan. J Gastroenterol. 2024, 59:1120-32. 10.1007\/s00535-024-02158-z","journal-title":"J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105319","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: a systematic review and meta-analysis of randomized controlled trials","volume":"163","author":"Simental-Mend\u00eda M","year":"2021","unstructured":"Simental-Mend\u00eda M, S\u00e1nchez-Garc\u00eda A, Rodr\u00edguez-Ram\u00edrez M, Simental-Mend\u00eda LE. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2021, 163:105319. 10.1016\/j.phrs.2020.105319","journal-title":"Pharmacol Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2022.101970","article-title":"Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"46","author":"Zafar Y","year":"2022","unstructured":"Zafar Y, Rashid AM, Siddiqi AK, et al.. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2022, 46:101970. 10.1016\/j.clinre.2022.101970","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1242241","article-title":"Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy","volume":"10","author":"Dong Y","year":"2023","unstructured":"Dong Y, Shi S, Liu L, Zhou X, Lv J, Zhang H. Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy. Front Med (Lausanne). 2023, 10:1242241. 10.3389\/fmed.2023.1242241","journal-title":"Front Med (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.2069","article-title":"Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus","volume":"6","author":"Arai T","year":"2022","unstructured":"Arai T, Atsukawa M, Tsubota A, et al.. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun. 2022, 6:3073-82. 10.1002\/hep4.2069","journal-title":"Hepatol Commun"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001036168.91510.a6","article-title":"SGLT-2 inhibitors: a therapeutic avenue for non-alcoholic fatty liver disease, demonstrating improvements in imaging biomarkers and histological features, including reduced hepatic fibrosis, and ballooning","volume":"119","author":"Sharma A","year":"2024","unstructured":"Sharma A, Daid SS, Sharma A, Daid S. SGLT-2 inhibitors: a therapeutic avenue for non-alcoholic fatty liver disease, demonstrating improvements in imaging biomarkers and histological features, including reduced hepatic fibrosis, and ballooning. Am J Gastroenterol. 2024, 119:S1237-8. 10.14309\/01.ajg.0001036168.91510.a6","journal-title":"Am J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002588","article-title":"Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes","volume":"35","author":"Ogawa Y","year":"2023","unstructured":"Ogawa Y, Nakahara T, Ando Y, et al.. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes. Eur J Gastroenterol Hepatol. 2023, 35:989-96. 10.1097\/MEG.0000000000002588","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita Y","year":"2022","unstructured":"Takeshita Y, Honda M, Harada K, et al.. Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care. 2022, 45:2064-75. 10.2337\/dc21-2049","journal-title":"Diabetes Care"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15437","article-title":"Glucose-lowering drugs and liver-related outcomes among individuals with type 2 diabetes: a systematic review of longitudinal population-based studies","volume":"41","author":"Khanmohammadi S","year":"2024","unstructured":"Khanmohammadi S, Habibzadeh A, Kamrul-Hasan AB, Schuermans A, Kuchay MS. Glucose-lowering drugs and liver-related outcomes among individuals with type 2 diabetes: a systematic review of longitudinal population-based studies. Diabet Med. 2024, 41:e15437. 10.1111\/dme.15437","journal-title":"Diabet Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106415","article-title":"A profile of SGLT-2 inhibitors in hyponatremia: the evidence to date","volume":"184","author":"Tang H","year":"2023","unstructured":"Tang H, Xu C, Zhang P, Luo T, Huang Y, Yang X. A profile of SGLT-2 inhibitors in hyponatremia: the evidence to date. Eur J Pharm Sci. 2023, 184:106415. 10.1016\/j.ejps.2023.106415","journal-title":"Eur J Pharm Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062253","article-title":"The effects of SGLT2 inhibitors on liver cirrhosis patients with refractory ascites: a literature review","volume":"12","author":"Miyamoto Y","year":"2023","unstructured":"Miyamoto Y, Honda A, Yokose S, Nagata M, Miyamoto J. The effects of SGLT2 inhibitors on liver cirrhosis patients with refractory ascites: a literature review. J Clin Med. 2023, 12:2253. 10.3390\/jcm12062253","journal-title":"J Clin Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7815690","article-title":"Empagliflozin increases short-term urinary volume output in artificially induced syndrome of inappropriate antidiuresis","volume":"2017","author":"Refardt J","year":"2017","unstructured":"Refardt J, Winzeler B, Meienberg F, Vogt DR, Christ-Crain M. Empagliflozin increases short-term urinary volume output in artificially induced syndrome of inappropriate antidiuresis. Int J Endocrinol. 2017, 2017:7815690. 10.1155\/2017\/7815690","journal-title":"Int J Endocrinol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13107","article-title":"Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed type 2 diabetes","volume":"33","author":"Wang Y","year":"2016","unstructured":"Wang Y, Xu L, Yuan L, et al.. Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed type 2 diabetes. Diabet Med. 2016, 33:1732-6. 10.1111\/dme.13107","journal-title":"Diabet Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1139\/y01-039","article-title":"Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure","volume":"79","author":"Yoshimura M","year":"2001","unstructured":"Yoshimura M, Yasue H, Ogawa H. Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. Can J Physiol Pharmacol. 2001, 79:730-5. 10.1139\/y01-039","journal-title":"Can J Physiol Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/cld.714","article-title":"SGLT2 inhibitors and cirrhosis: a unique perspective on the comanagement of diabetes mellitus and ascites","volume":"11","author":"Saffo S","year":"2018","unstructured":"Saffo S, Taddei T. SGLT2 inhibitors and cirrhosis: a unique perspective on the comanagement of diabetes mellitus and ascites. Clin Liver Dis (Hoboken). 2018, 11:141-4. 10.1002\/cld.714","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/cld.860","article-title":"Thrombocytopenia in cirrhosis: a review of pathophysiology and management options","volume":"14","author":"Moore AH","year":"2019","unstructured":"Moore AH. Thrombocytopenia in cirrhosis: a review of pathophysiology and management options. Clin Liver Dis (Hoboken). 2019, 14:183-6. 10.1002\/cld.860","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05498-0","article-title":"Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus","volume":"64","author":"Kohlmorgen C","year":"2021","unstructured":"Kohlmorgen C, Gerfer S, Feldmann K, et al.. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus. Diabetologia. 2021, 64:1834-49. 10.1007\/s00125-021-05498-0","journal-title":"Diabetologia"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003056","article-title":"Clinical implications of inflammation in patients with cirrhosis","volume":"120","author":"Kronsten VT","year":"2025","unstructured":"Kronsten VT, Shawcross DL. Clinical implications of inflammation in patients with cirrhosis. Am J Gastroenterol. 2025, 120:65-74. 10.14309\/ajg.0000000000003056","journal-title":"Am J Gastroenterol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.048","article-title":"The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis","volume":"74","author":"Arroyo V","year":"2021","unstructured":"Arroyo V, Angeli P, Moreau R, et al.. The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol. 2021, 74:670-85. 10.1016\/j.jhep.2020.11.048","journal-title":"J Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051263","article-title":"Anemia and systemic inflammation rather than arterial circulatory dysfunction predict decompensation of liver cirrhosis","volume":"9","author":"Bothou C","year":"2020","unstructured":"Bothou C, R\u00fcschenbaum S, Kubesch A, et al.. Anemia and systemic inflammation rather than arterial circulatory dysfunction predict decompensation of liver cirrhosis. J Clin Med. 2020, 9:1263. 10.3390\/jcm9051263","journal-title":"J Clin Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00476","article-title":"Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis","volume":"10","author":"Trebicka J","year":"2019","unstructured":"Trebicka J, Amoros A, Pitarch C, et al.. Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis. Front Immunol. 2019, 10:476. 10.3389\/fimmu.2019.00476","journal-title":"Front Immunol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1126\/science.1140485","article-title":"Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production","volume":"317","author":"Naugler WE","year":"2007","unstructured":"Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007, 317:121-4. 10.1126\/science.1140485","journal-title":"Science"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2011.05.005","article-title":"Hepatoprotective versus oncogenic functions of STAT3 in liver tumorigenesis","volume":"179","author":"Wang H","year":"2011","unstructured":"Wang H, Lafdil F, Wang L, et al.. Hepatoprotective versus oncogenic functions of STAT3 in liver tumorigenesis. Am J Pathol. 2011, 179:714-24. 10.1016\/j.ajpath.2011.05.005","journal-title":"Am J Pathol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/nature02924","article-title":"NF-\u03baB functions as a tumour promoter in inflammation-associated cancer","volume":"431","author":"Pikarsky E","year":"2004","unstructured":"Pikarsky E, Porat RM, Stein I, et al.. NF-\u03baB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004, 431:461-6. 10.1038\/nature02924","journal-title":"Nature"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47384-2","article-title":"Markers of inflammation predict survival in newly diagnosed cirrhosis: a prospective registry study","volume":"13","author":"Mynster Kronborg T","year":"2023","unstructured":"Mynster Kronborg T, Webel H, O'Connell MB, et al.. Markers of inflammation predict survival in newly diagnosed cirrhosis: a prospective registry study. Sci Rep. 2023, 13:20039. 10.1038\/s41598-023-47384-2","journal-title":"Sci Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108368","article-title":"A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress","volume":"168","author":"Bray JJ","year":"2020","unstructured":"Bray JJ, Foster-Davies H, Stephens JW. A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress. Diabetes Res Clin Pract. 2020, 168:108368. 10.1016\/j.diabres.2020.108368","journal-title":"Diabetes Res Clin Pract"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20176671","article-title":"Immunomodulatory effects of SGLT2 inhibitors\u2014targeting inflammation and oxidative stress in aging","volume":"20","author":"Sch\u00f6nberger E","year":"2023","unstructured":"Sch\u00f6nberger E, Mihaljevi\u0107 V, Steiner K, et al.. Immunomodulatory effects of SGLT2 inhibitors\u2014targeting inflammation and oxidative stress in aging. Int J Environ Res Public Health. 2023, 20:6671. 10.3390\/ijerph20176671","journal-title":"Int J Environ Res Public Health"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109080","article-title":"The impact of SGLT2 inhibitors on inflammation: a systematic review and meta-analysis of studies in rodents","volume":"111","author":"Theofilis P","year":"2022","unstructured":"Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis K, Tousoulis D. The impact of SGLT2 inhibitors on inflammation: a systematic review and meta-analysis of studies in rodents. Int Immunopharmacol. 2022, 111:109080. 10.1016\/j.intimp.2022.109080","journal-title":"Int Immunopharmacol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey WT","year":"2018","unstructured":"Garvey WT, Van Gaal L, Leiter LA, et al.. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018, 85:32-7. 10.1016\/j.metabol.2018.02.002","journal-title":"Metabolism"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111814","article-title":"The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes","volume":"8","author":"Iannantuoni F","year":"2019","unstructured":"Iannantuoni F, M de Mara\u00f1on A, Diaz-Morales N, et al.. The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes. J Clin Med. 2019, 8:1814. 10.3390\/jcm8111814","journal-title":"J Clin Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101549","article-title":"Cardiovascular protection by SGLT2 inhibitors - Do anti-inflammatory mechanisms play a role?","volume":"64","author":"Elrakaybi A","year":"2022","unstructured":"Elrakaybi A, Laubner K, Zhou Q, Hug MJ, Seufert J. Cardiovascular protection by SGLT2 inhibitors - Do anti-inflammatory mechanisms play a role?. Mol Metab. 2022, 64:101549. 10.1016\/j.molmet.2022.101549","journal-title":"Mol Metab"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1008922","article-title":"Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials","volume":"9","author":"Scisciola L","year":"2022","unstructured":"Scisciola L, Cataldo V, Taktaz F, et al.. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials. Front Cardiovasc Med. 2022, 9:1008922. 10.3389\/fcvm.2022.1008922","journal-title":"Front Cardiovasc Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102175","article-title":"The anti-inflammatory effects of SGLT inhibitors","volume":"11","author":"Garc\u00eda-Ropero \u00c1","year":"2019","unstructured":"Garc\u00eda-Ropero \u00c1, Santos-Gallego CG, Badimon JJ. The anti-inflammatory effects of SGLT inhibitors. Aging (Albany NY). 2019, 11:5866-7. 10.18632\/aging.102175","journal-title":"Aging (Albany NY)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink HJ","year":"2019","unstructured":"Heerspink HJ, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, Mayer G. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019, 62:1154-66. 10.1007\/s00125-019-4859-4","journal-title":"Diabetologia"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12469","article-title":"Cell-free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis","volume":"20","author":"Kozaki K","year":"2016","unstructured":"Kozaki K, IInuma M, Takagi T, et al.. Cell-free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis. Ther Apher Dial. 2016, 20:376-82. 10.1111\/1744-9987.12469","journal-title":"Ther Apher Dial"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31270","article-title":"Sodium\u2010glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes","volume":"72","author":"Montalvo-Gordon I","year":"2020","unstructured":"Montalvo-Gordon I, Chi-Cervera LA, Garc\u00eda-Tsao G. Sodium\u2010glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes. Hepatology. 2020, 72:1880-2. 10.1002\/hep.31270","journal-title":"Hepatology"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000995","article-title":"Empagliflozin eliminates refractory ascites and hepatic hydrothorax in a patient with primary biliary cirrhosis","volume":"116","author":"Kalambokis GN","year":"2021","unstructured":"Kalambokis GN, Tsiakas I, Filippas-Ntekuan S, Christaki M, Despotis G, Milionis H. Empagliflozin eliminates refractory ascites and hepatic hydrothorax in a patient with primary biliary cirrhosis. Am J Gastroenterol. 2021, 116:618-9. 10.14309\/ajg.0000000000000995","journal-title":"Am J Gastroenterol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.4081\/itjm.2024.1829","article-title":"Sodium-glucose cotransporter 2 inhibition in patients with liver cirrhosis and diabetes: a possible role in ascites control?","volume":"18","author":"Seidita A","year":"2024","unstructured":"Seidita A, Mandreucci F, Pistone M, et al.. Sodium-glucose cotransporter 2 inhibition in patients with liver cirrhosis and diabetes: a possible role in ascites control?. Ital J Med. 2024, 18:1829. 10.4081\/itjm.2024.1829","journal-title":"Ital J Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08667-4","article-title":"Safety and efficacy of dapagliflozin in recurrent ascites: a pilot study","volume":"70","author":"Singh V","year":"2025","unstructured":"Singh V, De A, Aggrawal R, Singh A, Charak S, Bhagat N. Safety and efficacy of dapagliflozin in recurrent ascites: a pilot study. Dig Dis Sci. 2025, 70:835-42. 10.1007\/s10620-024-08667-4","journal-title":"Dig Dis Sci"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2021.00418","article-title":"SGLT2 inhibitors: a new dawn for recurrent\/refractory cirrhotic ascites","volume":"9","author":"Gao Y","year":"2021","unstructured":"Gao Y, Wei L, Zhang DD, Chen Y, Hou B. SGLT2 inhibitors: a new dawn for recurrent\/refractory cirrhotic ascites. J Clin Transl Hepatol. 2021, 9:795-7. 10.14218\/JCTH.2021.00418","journal-title":"J Clin Transl Hepatol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/gox013","article-title":"Hepatic encephalopathy","volume":"5","author":"Ferenci P","year":"2017","unstructured":"Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017, 5:138-47. 10.1093\/gastro\/gox013","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.122.001289","article-title":"Sodium-glucose cotransporter-2 inhibition exacerbates hepatic encephalopathy in biliary cirrhotic rats","volume":"383","author":"Hsu SJ","year":"2022","unstructured":"Hsu SJ, Huang HC, Pun CK, et al.. Sodium-glucose cotransporter-2 inhibition exacerbates hepatic encephalopathy in biliary cirrhotic rats. J Pharmacol Exp Ther. 2022, 383:25-31. 10.1124\/jpet.122.001289","journal-title":"J Pharmacol Exp Ther"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2687","article-title":"Hepatorenal syndrome: pathophysiology, diagnosis, and management","volume":"370","author":"Simonetto DA","year":"2020","unstructured":"Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020, 370:m2687. 10.1136\/bmj.m2687","journal-title":"BMJ"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108330","article-title":"Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease","volume":"242","author":"Solomon J","year":"2023","unstructured":"Solomon J, Festa MC, Chatzizisis YS, Samanta R, Suri RS, Mavrakanas TA. Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease. Pharmacol Ther. 2023, 242:108330. 10.1016\/j.pharmthera.2022.108330","journal-title":"Pharmacol Ther"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15851","article-title":"Sodium-glucose linked transporter 2 inhibitors in liver cirrhosis: beyond their antidiabetic use","volume":"44","author":"Siafarikas C","year":"2024","unstructured":"Siafarikas C, Kapelios CJ, Papatheodoridi M, Vlachogiannakos J, Tentolouris N, Papatheodoridis G. Sodium-glucose linked transporter 2 inhibitors in liver cirrhosis: beyond their antidiabetic use. Liver Int. 2024, 44:884-93. 10.1111\/liv.15851","journal-title":"Liver Int"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i45.7831","article-title":"In-hospital mortality of hepatorenal syndrome in the United States: nationwide inpatient sample","volume":"27","author":"Kaewput W","year":"2021","unstructured":"Kaewput W, Thongprayoon C, Dumancas CY, et al.. In-hospital mortality of hepatorenal syndrome in the United States: nationwide inpatient sample. World J Gastroenterol. 2021, 27:7831-43. 10.3748\/wjg.v27.i45.7831","journal-title":"World J Gastroenterol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0001036756.32599.c9","article-title":"Exploring the therapeutic landscape: the impact of SGLT2 inhibitors on clinical outcomes in patients with cirrhosis","volume":"119","author":"Gudushauri N","year":"2024","unstructured":"Gudushauri N, Lemonjava I, Azmaiparashvili Z, et al.. Exploring the therapeutic landscape: the impact of SGLT2 inhibitors on clinical outcomes in patients with cirrhosis. Am J Gastroenterol. 2024, 119:S1330. 10.14309\/01.ajg.0001036756.32599.c9","journal-title":"Am J Gastroenterol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel EJ","year":"2020","unstructured":"van Bommel EJ, Muskiet MH, van Baar MJ, et al.. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int. 2020, 97:202-12. 10.1016\/j.kint.2019.09.013","journal-title":"Kidney Int"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32434","article-title":"Risk factors for HCC in contemporary cohorts of patients with cirrhosis","volume":"77","author":"Kanwal F","year":"2023","unstructured":"Kanwal F, Khaderi S, Singal AG, et al.. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023, 77:997-1005. 10.1002\/hep.32434","journal-title":"Hepatology"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat5933","article-title":"Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma","volume":"10","author":"Scafoglio CR","year":"2018","unstructured":"Scafoglio CR, Villegas B, Abdelhady G, et al.. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med. 2018, 10:eaat5933. 10.1126\/scitranslmed.aat5933","journal-title":"Sci Transl Med"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium-glucose transporters in cancer","volume":"112","author":"Scafoglio C","year":"2015","unstructured":"Scafoglio C, Hirayama BA, Kepe V, et al.. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A. 2015, 112:E4111-9. 10.1073\/pnas.1511698112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112864","article-title":"Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans","volume":"149","author":"Nakachi S","year":"2022","unstructured":"Nakachi S, Okamoto S, Tamaki K, et al.. Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans. Biomed Pharmacother. 2022, 149:112864. 10.1016\/j.biopha.2022.112864","journal-title":"Biomed Pharmacother"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232283","article-title":"Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)","volume":"15","author":"Nakano D","year":"2020","unstructured":"Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS One. 2020, 15:e0232283. 10.1371\/journal.pone.0232283","journal-title":"PLoS One"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106261","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: from molecular mechanisms to potential clinical implications","volume":"181","author":"Arvanitakis K","year":"2022","unstructured":"Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: from molecular mechanisms to potential clinical implications. Pharmacol Res. 2022, 181:106261. 10.1016\/j.phrs.2022.106261","journal-title":"Pharmacol Res"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000404","article-title":"SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: a territory-wide cohort study in Hong Kong","volume":"78","author":"Lee CH","year":"2023","unstructured":"Lee CH, Mak LY, Tang EH, et al.. SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: a territory-wide cohort study in Hong Kong. Hepatology. 2023, 78:1569-80. 10.1097\/HEP.0000000000000404","journal-title":"Hepatology"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274519","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis","volume":"17","author":"Hendryx M","year":"2022","unstructured":"Hendryx M, Dong Y, Ndeke JM, Luo J. Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis. PLoS One. 2022, 17:e0274519. 10.1371\/journal.pone.0274519","journal-title":"PLoS One"},{"key":"ref71","unstructured":"Effects of empagliflozin on fibrosis and cirrhosis in chronic hepatitis B. (2023). Accessed. April 30, 2025: https:\/\/clinicaltrials.gov\/study\/NCT05147090?term=NCT05147090&rank=1."},{"key":"ref72","unstructured":"Efficacy and safety of dapagliflozin in patients with non-alcoholic steatohepatitis. (2024). Accessed. April 30, 2025: https:\/\/clinicaltrials.gov\/study\/NCT05254626?term=NCT05254626&rank=1."},{"key":"ref73","unstructured":"Empagliflozin in diuretic refractory ascites. (2023). Accessed. April 30, 2025: https:\/\/clinicaltrials.gov\/study\/NCT05013502?term=NCT05013502&rank=1."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/366481-therapeutic-potential-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-in-liver-disease-focus-on-cirrhosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T12:11:05Z","timestamp":1748175065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/366481-therapeutic-potential-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-in-liver-disease-focus-on-cirrhosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":73,"URL":"https:\/\/doi.org\/10.7759\/cureus.84768","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,25]]}}}